计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| M413517-5mg |
5mg |
现货 ![]() |
| |
| M413517-10mg |
10mg |
现货 ![]() |
| |
| M413517-25mg |
25mg |
现货 ![]() |
| |
| M413517-50mg |
50mg |
现货 ![]() |
|
| 英文别名 | UNII-JKU4XCC48Y | NCGC00263773-01 | ML 355 | N-(1,3-benzothiazol-2-yl)-4-{[(2-hydroxy-3-methoxyphenyl)methyl]amino}benzene-1-sulfonamide | EX-A1987 | ML355 | ML-355 | AC-36858 | ML355 free base | VLX 1005 | SCHEMBL16646023 | ZR5 | HY-12341 | s6557 | N-2-B |
|---|---|
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | ML355 |
| 生化机理 | ML355 是一种强效的人 12 脂氧合酶选择性抑制剂,其 IC50 值为 290 nM,对相关脂氧合酶和环氧合酶具有极佳的选择性。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 12S-LOX 抑制剂 |
| 产品介绍 |
Information ML355 ML355 is a potent and selective inhibitor of human 12-Lipoxygenase with an IC50 of 290 nM and shows excellent selectivity over related lipoxygenases and cyclooxygenases. Targets 12-LOX In vitro ML355 displays nM potency against 12-LOX and excellent selectivity over related lipoxygenases and cyclooxygenases. In vivo In vivo PK studies where ML355 is administered as a solution via IV (3mpk) and PO (30mpk) demonstrated that ML355 is orally bioavailable (%F = 20) with good half-life (T1/2 = 2.9 hours). At 30 mpk dosing, ML355 achieves a Cmax of over 135 times the in vitro IC50 and remains over IC50 value for over 12 hours. The compound has low clearance (3.4 mL/min/kg) and good overall exposure (AUCinf) of 38 µM. Although, the volume of distribution (VD) observed is low (0.55 L/kg), the rest of the PK profiling results suggest a reasonable distribution between tissue and blood. |
| 纯度 | ≥98% |
| ALogP | 4.077 |
|---|---|
| hba_count | 4 |
| HBD Count | 3 |
| Rotatable Bond | 7 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504771987 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | N-(1,3-benzothiazol-2-yl)-4-[(2-hydroxy-3-methoxyphenyl)methylamino]benzenesulfonamide |
| INCHI | 1S/C21H19N3O4S2/c1-28-18-7-4-5-14(20(18)25)13-22-15-9-11-16(12-10-15)30(26,27)24-21-23-17-6-2-3-8-19(17)29-21/h2-12,22,25H,13H2,1H3,(H,23,24) |
| InChi Key | OWHBVKBNNRYMIN-UHFFFAOYSA-N |
| Smiles | COC1=CC=CC(=C1O)CNC2=CC=C(C=C2)S(=O)(=O)NC3=NC4=CC=CC=C4S3 |
| Isomeric SMILES | COC1=CC=CC(=C1O)CNC2=CC=C(C=C2)S(=O)(=O)NC3=NC4=CC=CC=C4S3 |
| 分子量 | 441.52 |
| Reaxy-Rn | 26556059 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=26556059&ln= |
| 溶解性 | Solubility (25°C) In vitro DMSO: 88 mg/mL (199.31 mM); Water: Insoluble; Ethanol: Insoluble; |
|---|---|
| DMSO(mg / mL) Max Solubility | 88 |
| DMSO(mM) Max Solubility | 199.311469469107 |
| Water(mg / mL) Max Solubility | <1 |
| 分子量 | 441.500 g/mol |
| XLogP3 | 4.300 |
| 氢键供体数Hydrogen Bond Donor Count | 3 |
| 氢键受体数Hydrogen Bond Acceptor Count | 8 |
| 可旋转键计数Rotatable Bond Count | 7 |
| 精确质量Exact Mass | 441.082 Da |
| 单同位素质量Monoisotopic Mass | 441.082 Da |
| 拓扑极表面积Topological Polar Surface Area | 137.000 Ų |
| 重原子数Heavy Atom Count | 30 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 651.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS07 |
|---|---|
| 信号词 | 警告 |
| 危险声明 |
H302: 吞食有害 H315: 引起皮肤刺激 H319: 引起严重眼睛刺激 H335: 可能引起呼吸道刺激 |
| 预防措施声明 |
P261: 避免吸入灰尘/烟雾/气体/雾/蒸汽/喷雾 P305+P351+P338: 如进入眼睛:用水小心冲洗几分钟。如戴隐形眼镜并可方便地取出,取出隐形眼镜。继续冲洗。 |
¥576.72
| 1. Luci DK, Jameson 2nd JB, Yasgar A, Diaz G, Joshi N, Kantz A, Markham K, Perry S, Kuhn N, Yeung J et al.. (2014) Synthesis and structure-activity relationship studies of 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase.. J Med Chem, 57 (2): (495-506). [PMID:24393039] |